By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Cyclobenzaprine

Cyclobenzaprine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
6 Min Read
SHARE
4 min read|742 words

Cyclobenzaprine: Uses, Side Effects, and Safety Information

What is Cyclobenzaprine?

Cyclobenzaprine is a centrally acting muscle relaxant that belongs to the tricyclic antidepressant class of medications, though it is not used as an antidepressant. It is primarily prescribed for the short-term treatment of muscle spasms and associated pain caused by acute musculoskeletal conditions. The medication is typically used in combination with rest and physical therapy to provide relief from muscle stiffness and discomfort.

Uses

Cyclobenzaprine is FDA-approved and commonly prescribed for several musculoskeletal conditions:

Acute muscle spasms: The primary indication is for relief of muscle spasms associated with acute, painful musculoskeletal conditions such as back strain or neck injury.

Lower back pain: Often prescribed as part of a comprehensive treatment plan for acute lower back pain when muscle spasms are present.

Submit Your Paper
GMJ_Submit_Banner

Neck pain and stiffness: Used to treat cervical muscle spasms and associated pain from conditions like whiplash or muscle strain.

Post-injury muscle tension: Helps reduce muscle tightness and pain following sports injuries or other trauma to muscles and soft tissues.

Fibromyalgia symptoms: While not FDA-approved for this use, some healthcare providers may prescribe cyclobenzaprine off-label to help manage muscle pain and improve sleep in fibromyalgia patients.

How it works

Cyclobenzaprine works by acting on the central nervous system, specifically in the brainstem, to reduce muscle tone and spasm. Unlike other muscle relaxants that work directly on muscle fibers, cyclobenzaprine appears to block nerve impulses that cause muscles to contract involuntarily. The medication also has sedative properties that can help patients rest and recover from muscle injuries.

Side effects

Common side effects include:

  • Drowsiness and fatigue
  • Dry mouth
  • Dizziness
  • Constipation
  • Blurred vision
  • Headache
  • Nausea
  • Confusion, especially in elderly patients

Serious side effects that require immediate medical attention:

  • Irregular heartbeat or chest pain
  • Severe allergic reactions with rash, swelling, or difficulty breathing
  • Seizures
  • Severe confusion or hallucinations
  • Signs of serotonin syndrome when combined with certain other medications

Warnings and precautions

Several important safety considerations apply to cyclobenzaprine use:

Contraindications: Patients with recent heart attack, heart rhythm disorders, heart failure, or hyperthyroidism should not take cyclobenzaprine. It is also contraindicated in those taking monoamine oxidase inhibitors (MAOIs).

Elderly patients: Older adults are at higher risk for falls, confusion, and other side effects due to increased sensitivity to the medication’s sedating and anticholinergic effects.

Pregnancy and nursing: Cyclobenzaprine is classified as pregnancy category B, meaning animal studies have not shown risk but human studies are lacking. The medication may pass into breast milk, so nursing mothers should discuss risks and benefits with their healthcare provider.

Liver impairment: Patients with liver disease may require dose adjustments or should avoid the medication entirely, as cyclobenzaprine is metabolized by the liver.

Short-term use only: The medication is intended for short-term use, typically no more than two to three weeks, as effectiveness for longer periods has not been established and dependence may develop.

Interactions

Cyclobenzaprine can interact with numerous medications and substances:

MAOIs: Dangerous, potentially life-threatening interactions can occur; cyclobenzaprine should not be used within 14 days of MAOI use.

CNS depressants: Alcohol, benzodiazepines, opioids, and sleep medications can increase drowsiness and respiratory depression when combined with cyclobenzaprine.

Serotonergic medications: SSRIs, SNRIs, triptans, and tramadol may increase the risk of serotonin syndrome when used with cyclobenzaprine.

Anticholinergic drugs: Medications like antihistamines, tricyclic antidepressants, and certain bladder medications can increase side effects like dry mouth, constipation, and confusion.

Thyroid medications: May enhance the effects of thyroid hormones, potentially causing cardiac arrhythmias.

Blood pressure medications: May interfere with the effectiveness of certain antihypertensive drugs.

St. John’s Wort: This herbal supplement may increase the risk of serotonin syndrome when combined with cyclobenzaprine.

Check interactions with the GMJ Interaction Checker

Dosage

For adults, the typical starting dose of immediate-release cyclobenzaprine is 5 mg three times daily, which may be increased to 7.5-10 mg three times daily based on response and tolerance. Extended-release formulations are usually dosed at 15-30 mg once daily. The maximum recommended daily dose is 30 mg for immediate-release tablets and 30 mg for extended-release capsules. Treatment duration should generally not exceed two to three weeks. Elderly patients and those with liver impairment typically require lower doses. Always follow your healthcare provider’s specific dosing instructions, as individual needs may vary based on the condition being treated and patient factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Cyclobenzaprine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/cyclobenzaprine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
FDA’s Pazdur Calls for Agency Restructuring Amid China Competition and Internal Upheaval

FDA's Rick Pazdur calls for fundamental agency restructuring following internal disruption, citing…

Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Vancomycin

By
Prof. Giorgi Pkhakadze
02/06/2026

Trazodone

By
Prof. Giorgi Pkhakadze
02/06/2026

Hydroxychloroquine

By
Prof. Giorgi Pkhakadze
02/06/2026

Milk Thistle (Silymarin)

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up